Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Rachel O. Abelman, Aditya Bardia, Geoffrey Fell et al.|Journal of Clinical Oncology|2023Cited by 53
TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerRachel O. Abelman, Aditya Bardia, Steven J. Isakoff et al.|Clinical Cancer Research|2025Cited by 39
Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker AnalysisRachel O. Abelman, Aditya Bardia, Steven J. Isakoff et al.|Cancer Research|2024Cited by 21
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Rachel O. Abelman, Aditya Bardia, Steven J. Isakoff et al.|Journal of Clinical Oncology|2024Cited by 6